{
    "initial_scores": {
        "ideological_tilt": -1,
        "immigration": 0,
        "executive_power": 3,
        "federalism": 1,
        "security_liberty": 0,
        "economic_regulation": -2,
        "social_inclusion": 0
    },
    "critique": "The document is an executive order focused on lowering prescription drug prices in the United States, specifically within the Medicare Part B program. It argues that Americans pay more for prescription drugs than other developed countries and aims to address this by implementing a 'most-favored-nation' pricing model, where Medicare pays no more than the lowest price at which the manufacturer sells the drug to any other developed nation. The order emphasizes the economic and health consequences of high drug prices, particularly for seniors, and seeks to ensure that the Federal Government, as the largest payer for prescription drugs, secures better prices.",
    "revised_scores": {
        "ideological_tilt": 0,
        "immigration": 0,
        "executive_power": 2,
        "federalism": 1,
        "security_liberty": 0,
        "economic_regulation": 4,
        "social_inclusion": 0
    }
}